Table 4:
rs7311358 | |||||||
---|---|---|---|---|---|---|---|
Risk of Death at One Year | Risk of Death at Three Years | ||||||
Overall Model |
Chi-square 22.082 p=0.002 |
Chi-square 11.298 p=0.080 |
|||||
Variable | Hazard Ratio | 95% CI | p-value | Hazard Ratio | 95% CI | p-value | |
Recipient Gender | 1.74 | 0.30–9.97 | 0.535 | 1.38 | 0.75–2.55 | 0.303 | |
Recipient Race, Nonwhite | 2.74 | 0.27–27.34 | 0.391 | 2.02 | 0.71–5.75 | 0.190 | |
Donor Race, Nonwhite | 3.72 | 0.69–20.10 | 0.127 | 1.53 | 0.80–2.90 | 0.197 | |
Cardiopulmonary Bypass | 0.62 | 0.11–3.42 | 0583 | 0.63 | 0.35–1.14 | 0.129 | |
No Acute Rejection at 1 year | 0.17 | 0.03–0.90 | 0.037 | -- | -- | -- | |
rs7311358: GG or GA | 7.76 | 1.37–44.04 | 0.021 | 1.97 | 1.04–3.72 | 0.036 | |
CNI: Cyclosporine vs. tacrolimus | 12.73 | 0.83–19.49 | 0.068 | 2.41 | 0.56–10.48 | 0.239 | |
rs4149117 | |||||||
Risk of Death at One Year | Risk of Death at Three Years | ||||||
Overall Model |
Chi-square 20.993 p=0.004 |
Chi-square 8.564 p=0.128 |
|||||
Variable | Hazard Ratio | 95% CI | p-value | Hazard Ratio | 95% CI | p-value | |
Recipient Gender | 1.63 | 0.29–9.12 | 0.586 | 1.36 | 0.74–2.51 | 0.318 | |
Recipient Race, Nonwhite | 2.22 | 0.22–22.26 | 0.498 | -- | -- | -- | |
Donor Race, Nonwhite | 4.08 | 0.75–22.17 | 0.103 | 1.51 | 0.79–2.87 | 0.205 | |
Cardiopulmonary Bypass | 0.62 | 0.11–3.38 | 0.576 | 0.67 | 0.38–1.20 | 0.181 | |
No Acute Rejection at 1 year | 0.18 | 0.04–0.96 | 0.045 | -- | -- | -- | |
rs4149117: TT or TG | 7.28 | 1.27–41.78 | 0.026 | 1.86 | 0.99–3.48 | 0.054 | |
CNI: Cyclosporine vs. tacrolimus | 12.28 | 0.83–182.69 | 0.069 | 2.23 | 0.53–9.95 | 0.265 |